

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Early Therapy Evaluation of Combined Anti-EGFR Antibody and Irinotecan in Orthotopic Pancreatic Tumor Xenografts

H. Kim¹, K. Folks¹, L. Guo², J. Sellers³, N. Fineberg⁴, C. Stockard³, W. Grizzle⁵, D. Buchsbaum⁶, D. Morgan¹, J. George², and K. Zinn¹

¹Radiology, University of Alabama at Birmingham, Birmingham, AL, United States, ²Surgery, University of Alabama at Birmingham, Birmingham, AL, United States,

³Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States, ⁴Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States, ⁵Pathology, University of Alabama at Birmingham, Birmingham, AL, United States, ⁶Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States

Purpose: To evaluate DCE-MRI as an early prognostic tool for effective anti-EGFR therapy with/without concurrent chemotherapy in an orthotopic pancreatic-cancer murine model, and to develop a novel timing-independent DCE-MRI biomarker for early therapy assessment, based on characterization of non-linear tumor response observed during serial imaging.

Methods: Groups 1-4 (n=6/group) of SCID mice bearing orthotopic pancreatic adenocarcinoma (luciferase-positive MIA PaCa-2) were treated with PBS (control), cetuximab (1mg), irinotecan (25mg/kg), or cetuximab plus irinotecan respectively twice weekly for 3 weeks. DCE-MRI was performed on days 0, 1, 2, and 3 after therapy initiation, while anatomical MRI was performed once weekly for 3 weeks. Bioluminescence imaging was performed on days 0 and 21. At day 21, all tumors were collected for CD31 and Ki-67 staining. Groups 5 (n=5) and 6 (n=4) were injected with Tc-99m-cetuximab and Tc-99m-isotype control antibody respectively; SPECT/CT imaging was performed at 6 hours after dosing, and biodistribution studies were performed at 24 hours after dosing. The averaged K^{trans} values in the entire tumor region or within the 0.5-mm thick peripheral tumor region were calculated. The best-fitting 2nd-order polynomial curves for the K^{trans} changes were retrieved, and the quadratic coefficient for each curve was proposed as the novel MR biomarker. K^{trans} , v_e , and tumor-volume measurements made among the groups 1-4 over 3 days (or 21 days for tumor volume) were analyzed using repeated measures analysis of variance (RM ANOVA). Comparisons for a single measurement were done using one-way ANOVA followed by Tukey's HSD (Honestly Significant Differences) test. The Pearson correlation coefficient was used to look at the relationships between two variables.

Results: *In vivo* SPECT/CT images visualized the significantly higher tumor uptake of Tc-99m-cetuximab than of Tc-99m-isotype control antibody, which was confirmed by biodistribution study; the tumor uptake of Tc-99m-cetuximab was 19.0 ± 0.6 %ID/g, which was significantly higher than that of Tc-99m-isotype control antibody (6.5 ± 1.2 %ID/g) ($p < 0.001$), whereas the blood concentration of Tc-99m-cetuximab (10.4 ± 0.5 %ID/g) was not different from that of Tc-99m-isotype control antibody (10.2 ± 2.8 %ID/g) ($p = 0.949$). Figure 1 shows representative dynamic contrast-enhanced MR images of a mouse at (A) 1 minute before and (B) 2 minutes after gadoteridol injection using the same intensity scale with (C,D) K^{trans} and (E,F) v_e maps of the (C,E) entire tumor regions or (D,F) 0.5-mm thick peripheral tumor regions. The boundary of the tumor region is indicated with a red dotted circle in Figs. 1A and 1B. The change in K^{trans} values of groups 1-4 for 3 days after therapy initiation were $83 \pm 33\%$, $63 \pm 28\%$, $17 \pm 16\%$, and $12 \pm 18\%$ respectively in the entire tumor region without statistical difference among any of the groups. However, when analyzed in peripheral tumor region, change in K^{trans} values were $102 \pm 16\%$, $42 \pm 21\%$, $15 \pm 6\%$, and $-19 \pm 5\%$ respectively (Fig. 2). The significant suppression of K^{trans} increase was detected after irinotecan ($p = 0.008$) or combination therapy ($p < 0.001$). The change in v_e values of groups 1-4 for 3 days after therapy initiation were $67 \pm 42\%$, $28 \pm 9\%$, $8 \pm 16\%$, and $-12 \pm 10\%$ respectively in the entire tumor region, while those in the peripheral tumor region were $77 \pm 43\%$, $26 \pm 12\%$, $13 \pm 11\%$, and $-20 \pm 7\%$ respectively, but no significant difference was detected among groups in either region. Figure 3 shows tumor-volume change of groups 1-4 during 21 days after therapy initiation; the mean tumor volumes of all four groups increased about 20% during the first 3 days without statistical difference ($p > 0.050$). However, for the entire 3 weeks, the tumor-volume increase was significantly suppressed by either monotherapy or combined therapy ($p < 0.050$). The K^{trans} changes observed for 3 days in the peripheral region were significantly correlated with tumor-volume changes ($p < 0.001$) and bioluminescence-signal changes ($p = 0.050$). The microvessel densities (CD31 stained) of groups 1-4 were $1.60 \pm 0.25\%$, $0.64 \pm 0.13\%$, $0.53 \pm 0.09\%$, and $0.27 \pm 0.05\%$ respectively, while the proliferating cell densities (Ki-67 stained) of groups 1-4 were $85.3 \pm 1.8\%$, $70.3 \pm 5.4\%$, $70.8 \pm 4.4\%$, and $48.3 \pm 7.1\%$ respectively. The K^{trans} changes for 3 days in peripheral region were significantly correlated with microvessel densities ($p = 0.002$) and proliferating-cell densities ($p = 0.001$). Of interest, the mean K^{trans} changes of all 4 groups in peripheral tumor region followed second-order polynomial curves, validated with high R^2 values (≥ 0.73). The quadratic coefficient of each curve was proposed as a novel DCE-MR based biomarker; the mean value of novel biomarker of groups 1-4 were 0.050 ± 0.026 , -0.015 ± 0.028 , -0.071 ± 0.021 , and -0.082 ± 0.013 respectively, and those of groups 3 and 4 were significantly lower than that of control ($p = 0.006$ and 0.003 respectively). The values of the novel biomarker were significantly correlated with tumor-volume changes ($p < 0.001$), bioluminescence-signal changes ($p = 0.019$), microvessel densities ($p = 0.002$), and proliferating-cell densities ($p = 0.001$).

Conclusion: This study supports the clinical use of DCE-MRI to evaluate an anti-EGFR therapy combined with chemotherapy for pancreatic adenocarcinoma, identifies a novel timing-independent DCE-MRI based biomarker, and proposes further application of this therapeutic surveillance strategy in human subjects to ultimately achieve more favorable patient-specific clinical outcomes.




Figure 1. Representative DCE-MR images at (A) 1 minute before and (B) 2 minutes after gadoteridol injection with (C,D) K^{trans} and (E,F) v_e maps of the (C,E) entire tumor regions or (D,F) 0.5-mm thick peripheral tumor regions.




Figure 2. K^{trans} changes of groups 1-4 during 3 days post therapy in the 0.5-mm thick peripheral tumor region.




Figure 3. Tumor volume changes of groups 1-4 during 21 days after therapy initiation.